BOYNTON BEACH, Fla., April 30, 2004 (PRIMEZONE) -- Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announced today research findings from the ongoing study on human breast cancer cells utilizing the Jacobson Resonator.
A total of 23 different pico-Tesla electromagnetic energy field (PTEMEF) schedules have been evaluated for their ability to alter the in-vitro viability of human mammary carcinoma cell types in tissue culture. Of these, two PTEMEF (Jacobson Resonance) schedules consistently suppressed the proliferation (growth) rate of this neoplastic cell type. Facilitated by the application of mRNA microarray technologies, subsequent investigations have discovered approximately eleven gene sequences that have their expression profiles altered in human mammary carcinoma cell populations following exposure to a specific PTEMEF schedule. These findings imply that PTEMEF schedules may be capable of influencing transcription events within human mammary carcinoma cell types.
Recent proteomics studies employing 2D-PAGE analysis and LC/mass spectrometry methodologies have discovered approximately 14 biological proteins produced by mammary carcinoma cell types that have their expression profiles altered following exposure to the same PTEMEF schedule applied in gene-expression investigations. Interpretation of these findings further supports speculation that PTEMEF schedules can potentially alter transcription/translation events in populations of human mammary carcinoma.
Ongoing and future research investigations will be devoted to determining the (i) degree of correlation that exist between alterations in the expression profiles for genetic mRNA sequences and changes in the production of biological protein fractions induced by exposure to PTREMF schedules; and (ii) qualitative (functional) differences in biological protein fractions induced by exposure to PTREMF schedules.
Dr. Jerry I. Jacobson, JRSE Chairman, Chief Executive Officer and Chief Science and Technology Officer said: "It has now been demonstrated that calculated Jacobson Resonance Fields can kill human breast cancer cells in-vitro while restructuring numerous cancer genes. Additionally, remarkable changes in translated proteins may yield new targets for pharmaceutical agents thus making Jacobson Resonators not only therapeutic tools but valuable aids in research and diagnostics. Indeed, ongoing genetic studies and proteomics promise new inroads in cancer research. Concomitant clinical studies in Nassau have revealed, albeit anecdotal at the present time, profound results in cancer therapy."
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of healthcare, veterinary medicine, the leisure and spa, beauty and sports arenas, food and beverage, pharmaceuticals, energy and the environment.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances. For further information, contact Anthony P. Fusco, Jr. at (561) 752-4141.